R&D Trends

NIH funds new studies on the impact of genomic information

Tuesday, May 17, 2016

Four new grants from the National Institutes of Health will support research on the ethical, legal and social questions raised by advances in genomics research and the increasing availability of genomic information. The awards will fund researchers at interdisciplinary centers through the National Human Genome Research Institute’s (NHGRI) Centers of Excellence in Ethical, Legal and Social Implications Research (CEER) program.

[Read More]

Sanofi, Johns Hopkins partner on multiple sclerosis research

Monday, May 16, 2016

Sanofi Genzyme, the specialty care global business unit of Sanofi, has announced a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.

[Read More]

AVROBIO awarded Johnson & Johnson JLabs Incubator Space

Monday, May 16, 2016

AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, has been awarded lab space at Johnson & Johnson’s (J&J) newest JLABS facility in Toronto, Ontario. AVROBIO, headquartered in Cambridge, Massachusetts, with researchers in Toronto, will join other early stage companies in the 40,000 square foot facility opening this spring.

[Read More]

DCRI, SAS open heart-disease data to researchers

Monday, May 9, 2016

A new collaboration between the Duke Clinical Research Institute (DCRI) and SAS will give more researchers access to the largest and oldest cardiovascular database in the world. The DCRI and analytics leader SAS will provide researchers worldwide with data management and analytics tools to explore 45 years of cardiovascular patient data collected by the Duke University Health System.

[Read More]

WAVE, Pfizer partner on metabolic diseases

Thursday, May 5, 2016

WAVE Life Sciences has entered into a research, license and option agreement with Pfizer for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together WAVE’s proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer’s hepatic targeting technology for enhanced delivery to the liver.

[Read More]

EMD Serono expands biopharmaceutical R&D facility in Massachusetts

Tuesday, May 3, 2016

EMD Serono, the biopharmaceutical business of Merck, Darmstadt, Germany, in North America, has announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.

[Read More]